Scrutinize the data and tweets to envisage if the closing price of $gild will swell or contract at 2017-01-20. Please affirm either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-01-05,1.1,1.1,-0.6,-0.5,-0.5,-2.6,-2.9,-2.5,-2.9,-3.3,-3.1
2017-01-06,1.3,1.3,-0.1,-0.7,-0.7,-1.0,-2.1,-1.9,-2.1,-2.5,-2.4
2017-01-09,0.1,0.3,-0.8,0.5,0.5,-0.3,-2.2,-2.3,-2.2,-2.8,-2.8
2017-01-10,1.9,2.0,-0.1,-1.1,-1.1,1.0,-0.9,-1.1,-1.0,-1.6,-1.7
2017-01-11,2.4,2.4,-1.0,-1.7,-1.7,2.0,0.7,0.5,0.7,0.2,-0.1
2017-01-12,0.2,0.4,-0.6,-0.6,-0.6,1.8,1.4,1.0,1.2,0.8,0.4
2017-01-13,0.8,1.0,-0.1,-0.4,-0.4,1.6,1.9,1.3,1.4,1.3,0.8
2017-01-17,1.4,1.4,-0.3,-1.6,-1.6,2.1,3.6,2.8,2.8,2.9,2.4
2017-01-18,0.2,0.5,-0.9,0.3,0.3,1.0,3.0,2.3,2.4,2.6,2.1
2017-01-19,0.3,1.0,-0.5,-0.8,-0.8,1.2,3.1,2.9,3.0,3.3,2.9

2017-01-05: valeant is a strong acquisition target  $vrx, $amgn, $gild, $pfe|$gild - buy signal at 76.38 on jan 04, 17 by  trading robot#stockstowatch #stockmarket #trading #trade #investing|AT_USER AT_USER you t
2017-01-06: investors buy shares of gilead sciences, inc. $gild on weakness on insider selling |long $ezu $pawn $cresy $gild $pbr $dow $nflx short $eur.usd|rt AT_USER how will #jpm17 impact equity valuations for 
2017-01-07: AT_USER from cs crowded report from us funds - $gild fading star - $celg almost a darling |beaten-down gilead is my top 2017 pick   $gild #dividend #investing |biotech preview for 2017. small cap shou
2017-01-08: #gileadsciences phenex pharmaceuticals ag receives $100m milestone payment from gilead  . read more:  $gild|forget #gileadsciences inc.: these 2 stocks doubled last year. read more:  $gild|#gileadscie
2017-01-09:  &lt;&lt; top stock pick services fully reviewed! $fb $baba $gild $sbux|rt AT_USER 'AT_USER tells us he's not looking at gilead $gild|earlier on fast money, icahn denied $gild activism rumors|4 things
2017-01-10: rt AT_USER $gild ceo on fast money: we will be looking for partnerships &amp; m&amp;a for pipeline growth. it has to be complementary to¡­|$sgmo could be a dark horse aquisition for $gild hiv franchis
2017-01-11: rt AT_USER over $22m in grants from gilead to study three areas of #hiv cure research  $gild|rt AT_USER $gild told analysts at mtg today they might separate out hcv and/or hiv product guidance for 201
2017-01-12: added to $adnt today at close and i'll be stalkin any weakness in biotech from overreaction to trump $gild $celg $ions $agn &amp; several others|commented on will 2017 be different for gilead sciences
2017-01-13: AT_USER AT_USER your opinion on $gild. it is now creating a base at $73. is it worth buying, what is the cyclicality for biotech?|do you know that #book value for $gild is $12.76 |the threats and oppo
2017-01-14: rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $icpt $gild $cnat $gnftf $ibb $ccxi |rt AT_USER AT_USER nash pipeline.   nowhere complete but good one to start $agn $ic
2017-01-15: ok. twitter it is. sshh. don't tell anybody. ha $vrx $agn $myl $ko $pep $twtr $aapl $amzn $googl $gild $hlf $iep $azn $dis $sgen $ipxl $qure|must read: top trading &amp; investment resources. link:  $
2017-01-16: rt AT_USER 20 cheapest stocks in $spx on p/e basis, but are they cheap vs their 10y historical median valuations? $endp $gm $mnk $m¡­|commented on gilead goal 2018 - changing the conversation  $gild|2
2017-01-17: AT_USER AT_USER AT_USER $gild rsv compound is a fusion rsv inhibitor as well. expect similar data.|AT_USER AT_USER do these data have long term implications for the co? probably not, w/ likely superio
2017-01-18: rt AT_USER govt should buy $gild at premium. would ¡ý hep c drug costs per pt by 63% mark trusheim and i explain AT_USER op-ed |rehmann capital advisory group has $1,185,000 position in gilead science
2017-01-19: botty investors llc has $1,582,000 position in gilead sciences inc. $gild |will AT_USER inaugural speech cause $ibb $xbi $celg $amgn $clvs $biib $uthr $gild to:|rt AT_USER cure your portfolio with gil
Answer:
Fall